Analysts expect ADMA Biologics to report Q2 2026 revenue of $125.34 million and EPS of $0.16, as the stock trades near $8.46 against a median analyst price target of $17.00. Investors are primarily focused on management's response to ongoing securities fraud litigation alleging revenue manipulation through a "channel-stuffing" scheme involving its flagship product, ASCENIV.
The company is under significant pressure following a sharp year-to-date decline triggered by a 2026 short-seller report and subsequent cuts to full-year guidance. Despite the legal overhang, analysts are watching for signs of resilient underlying demand for ASCENIV and continued gross margin expansion to validate the company's long-term commercial trajectory.